[Editorial] Lenacapavir—time to change the game for everyone

Lenacapavir is a twice-yearly injectable drug produced by Gilead Sciences that is aimed at preventing HIV infection. In 2024, the findings of the PURPOSE 1 and PURPOSE 2 trials testing lenacapavir for HIV prevention showed 100% efficacy in preventing HIV in 5300 cisgender women in Uganda and South Africa, and a 96% reduction in HIV incidence among cisgender men and trans and non-binary individuals across multiple countries. Lenacapavir represents a major step forwards in prevention options for people at risk of HIV infection when compared with daily oral pre-exposure prophylaxis (PrEP), which can create issues of adherence and stigma.